Veradigm (AL21) Stock Overview

A healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. More details

AL21 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings are forecast to grow 19.5% per year

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

AL21 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Veradigm Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Veradigm
Historical stock prices
Current Share Price	US$3.60
52 Week High	US$3.60
52 Week Low	US$3.60
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-55.00%

Recent updates

Shareholder Returns

	AL21	DE Healthcare Services	DE Market
7D	0%	0.2%	-1.0%
1Y	n/a	13.6%	10.1%

Return vs Industry: Insufficient data to determine how AL21 performed against the German Healthcare Services industry.

Return vs Market: Insufficient data to determine how AL21 performed against the German Market.

Price Volatility

Is AL21's price volatile compared to industry and market?
AL21 volatility
AL21 Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	4.4%
Market Average Movement	5.2%
10% most volatile stocks in DE Market	12.8%
10% least volatile stocks in DE Market	2.6%

Stable Share Price: AL21's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine AL21's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1986	n/a	Don Trigg	veradigm.com

Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS, EHR software, veradigm EHR, and practice fusion EHR; and patient engagement platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as veradigm connect, veradigm app expo, and diagnostic ordering and resulting network; life sciences, health plans and payers, and providers; and veradigm eprescribe enterprise.

Veradigm Inc. Fundamentals Summary

How do Veradigm's earnings and revenue compare to its market cap?
AL21 fundamental statistics
Market cap	€708.28m
Earnings (TTM)	-€16.96m
Revenue (TTM)	€497.40m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is AL21 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AL21 income statement (TTM)
Revenue	US$588.02m
Cost of Revenue	US$279.60m
Gross Profit	US$308.42m
Other Expenses	US$328.46m
Earnings	-US$20.04m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did AL21 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/01/23 17:02
End of Day Share Price	2026/01/23 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Veradigm Inc. is covered by 29 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
Matthew Gillmor	Baird
Lawrence Marsh	Barclays

Veradigm Inc.BST:AL21 Stock Report